The use of pegylated interferon alfa-2b for the manufacture of a medicament for the treatment of a patient who has renal cell carcinoma, wherein said medicament has to be administered in a therapeutically effective dose of pegylated interferon alfa-2b once per week for a period of at least 12 months, in which the pegylated interferon alfa-2b comprises polyethylene glycol having an average molecular weight of 12,000 and the therapeutically effective dose of about 4.5 µg / kg to about 9.0 µg / kg .
展开▼
